Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial

Leuk Lymphoma. 2022 Mar;63(3):762-764. doi: 10.1080/10428194.2021.2001467. Epub 2021 Nov 8.

Authors

Amer M Zeidan¹, Cynthia Z Qi², Hongbo Yang², Andy Garnham³, Manasee V Shah³, Bhavik J Pandya³

Affiliations

¹ Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.
² Analysis Group, Inc., Boston, MA, USA.
³ Astellas Pharma, Inc., Northbrook, IL, USA.

PMID: 34749571
DOI: 10.1080/10428194.2021.2001467

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aniline Compounds / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Pyrazines* / therapeutic use
Salvage Therapy
fms-Like Tyrosine Kinase 3 / genetics

Substances

Aniline Compounds
Pyrazines
gilteritinib
FLT3 protein, human
fms-Like Tyrosine Kinase 3